Clinical utilization of testing for cell-free DNA in hepatocellular cancer
- 14 January 2026
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (4) , 1096-1120
Abstract
HCC is one of the leading causes of cancer-related death globally. HCCs are often diagnosed in advanced stages, and most patients are not eligible for curative treatments. Semiannual abdominal ultrasound with serum alpha-fetoprotein is the current recommended surveillance strategy; however, it has suboptimal sensitivity and implementation, thereby lowering its effectiveness for early-stage HCC detection. Further, post-treatment monitoring of HCC recurrence or progression is not tailored to tumor aggressiveness. These failures highlight critical unmet needs, which can be addressed by novel biomarkers that enable early detection and guide individualized surveillance and post-treatment follow-up for HCC, ultimately leading to improved outcomes in this disease. Cell-free DNA (cfDNA), consisting of small fragments of DNA released from tumor and normal cells into the bloodstream, reflects tumor-specific molecular alterations and has emerged as a promising noninvasive biomarker. This review summarizes recent advances in cfDNA applications in HCC, including risk stratification, early detection, prognostication, and minimal residual disease assessment. Among them, cfDNA has made the most progress in early detection. cfDNA assays, combined with clinical and serum parameters, demonstrate sensitivity noninferior or superior to ultrasound for detecting early HCC, with larger phase 3 validation studies ongoing. In contrast, the use of cfDNA for risk stratification, prognostication, and minimal residual disease detection remains in the early stages of clinical development. Future multicenter studies with standardized methodologies and rigorous validation will be essential to translate cfDNA into routine clinical practice for the management of HCC.Keywords
This publication has 106 references indexed in Scilit:
- Non‐Invasive Tumor‐Naïve Minimal Residual Disease Detection of Liver Cancer by Incorporating Circulating Tumor DNA Features and Alpha‐Fetoprotein: A Prospective StudyCancer Medicine, 2024
- Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort studyClinical and Translational Medicine, 2024
- Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC)Molecular Oncology, 2023
- Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinomaMolecular Oncology, 2021
- Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective studyMolecular Oncology, 2021
- Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular CarcinomaHepatology, 2021
- Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular CancerHepatology, 2020
- Hepatocellular carcinoma tumour burden score to stratify prognosis after resectionBritish Journal of Surgery, 2020
- Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical ValidationHepatology, 2019
- Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapyHepatology, 2015